C. Bellantuono, E. Spina - Vol. 8, March 2002, Issue 1
Testo Immagini Bibliografia Summary Indice
Il trattamento degli stati di agitazione
psicotica con olanzapina iniettabile. Aspetti farmacologici e clinici
The treatment of psychotic states with injectable olanzapine. Pharmacological
and clinical aspects
1 Meltzer HY. Pre-clinical pharmacology of atypical antipsychotic drugs: a selective review. Br J Clin Psychiatry 1996;168(Suppl. 29):23-31.
2 Kinon BJ, Lieberman JA. Mechanism of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology 1996;124:2-34.
3 Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996;153:466-76.
4 Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001;158:360-9.
5 Robertson GS, Fibiger HC. Effects of olanzapine on regional C-Fos expression in rat forebrain. Neuropsychopharmacology 1996;14:105-10.
6 Stephenson CME, Pilowsky LS. Psychopharmacology of olanzapine: a review. Br J Psychiatry 1999;174(Suppl. 38):52-8.
7 Fulton B, Goa KL. Olanzapine: a review on its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 1997;53:281-98.
8 Tollefson GD, Taylor CC. Olanzapine: preclinical and clinical profiles of a novel antipsychotic agent. CNS Drugs Reviews 2000;6:303-63.
9 Bhana N, Foster RH, Olney R, Plosker GL. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs 2001;61:111-61.
10 Moore NA, Tye NC, Axton MS, Risius FC. The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 1992;262:545-51.
11 Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999;156:286-93.
12 Li XM, Perry KW, Wong DT, Bymaster FP. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology 1998;136:153-61.
13 Corson PW, Nopoulos P, Miller DD, et al. Change in basal ganglia volume over 2 years in patients with schizophrenia: typical versus atypical neuroleptics. Am J Psychiatry 1999;156:1200-4.
14 Crawford AM, Beasley CM Jr, Tollefson GD. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 1997;26:41-54.
15 Kassahun K, Mattiuz E, Nyhart E, et al. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos 1997;25:81-93.
16 Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine: pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999;37:177-93.
17 Spina E, Scordo MG. Newer antipsychotics: comparative review of drug interactions. Exp Rev Neurother 2001;1:171-82.
18 Ring BJ, Binkley SN, Vandenbranden M, Wrighton SA. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C19, CYP2C10, CYP2D6, and CYP3A. Br J Clin Pharmacol 1996;41:181-6.
19 Callaghan JT, Cerimele BJ, Kassahun KJ, Nyhart EH, Hoyes-Beehler PJ, Kondraske GV. Olanzapine: interaction study with imipramine. J Clin Pharmacol 1997;37:971-8.
20 Macias WL, Bergstrom RF, Cerimele BJ, Kassahun K, Tatum DE, Callaghan JT. Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men. Pharmacotherapy 1998;18:1237-48.
21 Maenpaa J, Wrightson S, Bergstrom R, et al. Pharmacokinetic (PK) and pharmacodynamic (PD) interactions between fluvoxamine and olanzapine (abstract). Clin Pharmacol Ther 1997;61:225.
22 De Jong J, Hoogenboom B, van Troostwijck LD, De Hann L. Interaction of olanzapine with fluvoxamine. Psychopharmacology 2001;156:219-20.
23 Markowitz JS, DeVane CL. Suspected ciprofloxacin inhibition of olanzapine resulting in increased plasma concentrations. J Clin Psychopharmacol 1999;19:289-91.
24 Lucas RA, Gilfillan DJ, Bergstrom RF. A pharmacokinetic interaction between carbamazepine and olanzapine: Observations on possible mechanisms. Eur J Clin Pharmacol 1998;54:639-43.
25 Olesen OV, Linnet K. Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication. Ther Drug Monit 1999;21:87-90.
26 Licht RW, Olesen OV, Friis P, Laustsen T. Olanzapine serum concentrations lowered by concomitant treatment with carbamazepine. J Clin Psychopharmacol 2000;20:110-2.
27 Madhusoodanan S, Brenner R, Suresh P, et al. Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study. Ann Clin Psychiatry 2000;12:11-8.
28 Klimke A, Klieser E. Sudden death after i.v. application of lorazepam in a patient treated with clozapine. Am J Psychiatry 1994;151:780.
29 Jackson CW, Markowitz JS, Brewerton TD. Delirium associated with clozapine and benzodiazepine combinations. Ann Clin Psychiatry 1995;7:139-41.
30 Tupala E, Niskanen L, Tiihonen J. Transient syncope and ECG changes associated with concurrent administration of clozapine and diazepam. J Clin Psychiatry 1999;60:619-20.
31 Bellantuono C, Vampini C, Balestrieri. Psicofarmacoterapia della schizofrenia. In: Bellantuono C, Balestrieri M, eds. Psicofarmaci: Farmacologia e Terapia. Roma: Il Pensiero Scientifico Editore 1997.
32 De Rossi M, Donda P, Bellantuono C. Efficacia e tollerabilità di olanzapina. Una rassegna della letteratura internazionale. Riv Psichiatr 2001;36.
33 Bellantuono C, Vampini C, Balestrieri M. I Nuovi Antipsicotici. Seconda Edizione. Roma: Il Pensiero Scientifico Editore 2001.
34 Gomez JC, Sacristan JA, Hernandez J, Breier A, Ruiz Carrasco P, Anton Saiz C, et al. for the EFESO Study Group. The safety of olanzapina compared with other antipsychotic drugs: results of an observational prospective styudy in patients with schizophrenia. J Clin Psychiatry 2000;61:335-43.
35 Allison et al. Random blood glucose levels in Patients with Schizophrenia treated with Typical and atypical Antipsychotics Agents: an analysis of data from double-blind, randomized controlled clinical trias. Presented at the International Congress on Schizophrenia Research, April 29, 2001, Whistler, British Columbia, Canada.
36 Fleishhacker WW. The pharmacological treatment of schizophrenia. In: Maj M, Sartorius N, eds. Schizophrenia. Chicester, England: John Wiley & Sons 1999.
37 Marder SR. Newer antipsychotics. Curr Opin Psychiatry 2000;13:11-4.
38 Moller HJ. State of art of drug treatmentof schizophrenia and future positionof the novel antipsychotics. World J Biol Psychiatry 2000:204-14.
39 Jones B, Taylor C, Meehan K. The efficacy of a rapid-acting intramuscolar formulation of olanzapine for positive symptoms. J Clin Psychiatry 2001;62(suppl. 2):22-4.
40 Wright P, Birkett M, David SR, Meehan K, Ferchland I, Alaka KJ, et al. Double-blind, placebo controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001;158:1149-51.
41 Meehan K, Zhang F, David S, Tohen M, Janicak P, et al. A double blind, randomized comparison of the efficacy and safety of intramuscular injiections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001;21:389-97.
42 Awad AG, Hogan TP, Voruganti INP, Heslegrave RG. Patient’s subjective experience on antipsychotic medication: implications for compliance and outcome. Int Clin Psychopharmacol 1996;11:55-9.
Ulteriori fonti bibliografiche
Arnt J, Skarsfeldt T. Do novel antipsychotic have similar pharmacological characteristics? A review of evidence. Neuropsychopharmacol 1998;18:63-101.
Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacol 1996;14:111-23.
Deshauer D, Albuquerque J, Alda M, Grof P. Seizures caused by possible interaction between olanzapine and clomipramine. J Clin Psychopharmacol 2000;20:283-4.
Gomberg RF. Interaction between olanzapine and haloperidol. J Clin Psychopharmacol 1999;19:272-3.
Li XM, Chlan-Fourney J, Juorio AV, et al. Differential effects of olanzapine on the gene expression of superoxide dismutase and the low affinity nerve growth factor receptor. J Neurosci Res 1999;56:72-5.